3 Stocks I Saw on T...
Health Care: Drugs
Ariad Pharmaceuticals (ARIA: NASDAQ)
$15.63 -0.08 | -0.51%
06/04/12 - 04:00 PM ET
Company Income Statement
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Sales | 25.30M | 178.98M | 8.30M | 7.08M |
| Cost of Sales | -4.61M | -6.15M | -4.22M | -3.02M |
| Gross Operating Profit | 29.91M | 185.13M | 12.52M | 10.10M |
| Selling, General, and Administrative Expenses | 24.38M | 16.10M | 16.89M | 28.09M |
| Research & Development | 77.74M | 57.98M | 63.45M | 50.84M |
| Operating Income before D & A (EBITDA) | -72.21M | 111.05M | -67.81M | -68.84M |
| Depreciation & Amortization | 4.61M | 6.15M | 4.22M | 3.02M |
| Interest Income | 167.00K | 86.00K | 116.00K | 1.35M |
| Other Income - Net | -46.72M | -19.53M | -7.80M | 0.00 |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -123.37M | 85.45M | -79.72M | -70.50M |
| Interest Expense | 232.00K | 206.00K | 287.00K | 550.00K |
| Pre-Tax Income | -123.60M | 85.25M | -80.01M | -71.05M |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -123.60M | 85.25M | -80.01M | -71.05M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -123.60M | 85.25M | -80.01M | -71.05M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -123.60M | 85.25M | -80.01M | -71.05M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-123.60M | 85.25M | -80.01M | -71.05M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -123.60M | 85.25M | -80.01M | -71.05M |
| Basic EPS from Continuing Ops. | -0.93 | 0.75 | -0.86 | -1.02 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.93 | 0.75 | -0.86 | -1.02 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.93 | 0.75 | -0.86 | -1.02 |
| Basic Normalized Net Income/Share | -0.93 | 0.75 | -0.86 | -1.02 |
| EPS fr Continuing Ops. | -0.93 | 0.74 | -0.86 | -1.02 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.93 | 0.74 | -0.86 | -1.02 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.93 | 0.74 | -0.86 | -1.02 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.93 | 0.74 | -0.86 | -1.02 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with ARIA
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- Contributor7 Cancer Drug Stocks to Kno...
- ContributorStocks At New 52-Week Highs...
- ContributorStocks Rising On Unusual Vo...
- Contributor10 Biotech Stocks Loved and...
- ContributorEarnings Short Squeeze Play...
- Contributor5 Stocks Under-$10 Setting ...
- Userlance and donna
- ContributorHot Biotech Trades for Seco...
Latest ARIA Headlines from TheStreet
- ASCO 2012 Live Blog -- Monday 06.04.12 | 06:06 am
- ASCO '12: Ariad Pharma Leukemia Drug Posts Improved Response Rates 06.04.12 | 12:06 am
- Biotech Stock Mailbag: ASCO, Celldex, Obesity Drug Game-Changer 05.25.12 | 05:05 am
- The Next Big Thing in Biotech: ASCO Conference
05.25.12 | 05:05 am - ASCO '12 Abstract Dump: Cancer Stocks in Focus (Update) 05.17.12 | 06:05 am
- ASCO '12 Abstract Dump: Cancer Stocks in Focus 05.16.12 | 06:05 pm
- Ariad Stock Hits New 52-Week High (ARIA) 05.11.12 | 01:05 pm
- Ariad Reaches New 52-Week High (ARIA) 04.27.12 | 11:04 am
- Endocyte Shares Rise on Merck Cancer Deal 04.16.12 | 09:04 am
- Analysts' Actions: ARIA, EA, HGSI, BBBY 04.12.12 | 08:04 am
Press Releases for ARIA
- ARIAD Announces Updated Data From Pivotal PACE Trial Of Ponatinib, Its Investigational Pan-BCR-ABL Inhibitor - Business Wire 06.04.12 | 07:06 am
- ARIAD To Present At Upcoming Investor Conferences - Business Wire 05.30.12 | 07:05 am
- ARIAD To Present At Bank Of America Merrill Lynch 2012 Health Care Conference - Business Wire 05.10.12 | 07:05 am
- ARIAD To Present At The Deutsche Bank 37th Annual Health Care Conference - Business Wire 04.30.12 | 07:04 am
- ARIAD To Webcast Conference Call On First Quarter 2012 Financial Results - Business Wire 04.25.12 | 07:04 am
- ARIAD Presents New Preclinical Data On Ponatinib And AP26113 - Business Wire 04.02.12 | 09:04 am
- ARIAD Announces Presentations Of Preclinical Data At American Association For Cancer Research Annual Meeting - Business Wire 03.26.12 | 07:03 am
- Merck And ARIAD Pharmaceuticals Provide Update On FDA Advisory Committee Vote On Investigational Medicine Ridaforolimus For The Treatment Of Metastatic Soft-Tissue Or Bone Sarcomas - Business Wire 03.20.12 | 07:03 pm
- ARIAD To Present At Barclays Capital Global Healthcare Conference - Business Wire 03.06.12 | 07:03 am
- ARIAD Reports 2011 Financial Results And Outlines Key Development And Commercialization Plans For 2012 - Business Wire 02.28.12 | 07:02 am
Partner Headlines for ARIA
- AACR Annual Oncology Meeting: A Look Into Various Abstracts - Seeking Alpha 03.27.12 | 09:03 am
- Zacks #5 Rank Additions for Thursday - Tale of the Tape - Zacks 03.22.12 | 09:03 am
- Zacks #5 Rank Additions for Wednesday - Tale of the Tape - Zacks 03.14.12 | 09:03 am
- Zacks #5 Rank Additions for Tuesday - Tale of the Tape - Zacks 02.28.12 | 09:02 am
- Notable Put Options Activity in ARIAD Pharmaceuticals - Benzinga 02.02.12 | 01:02 pm
- Biotech Equities Continue To Benefit From Discoveries And Acquisitions In 2012 - Seeking Alpha 01.27.12 | 09:01 am
- 10 Stocks That Made New Highs On Friday: Hedging Costs - Seeking Alpha 01.15.12 | 07:01 am
- Using Friday's Option Trades To Find Investment Ideas - Seeking Alpha 01.13.12 | 06:01 pm
- YM's Positive Results Have Incyte Investors Worried - Seeking Alpha 12.15.11 | 09:12 am
- Rodman & Renshaw Maintain Market Outperform Rating and $15 PT on ARIAD Pharmaceuticals - Benzinga 11.01.11 | 09:11 am
